Oncologist Charles Blanke reflects on cancer research journey and push for medical aid in dying

The latest episode of the "How This Is Building Me" podcast features D. Ross Camidge, MD, PhD, speaking with Charles D. Blanke, MD, a professor at Oregon Health & Science University. The conversation explores the full arc of Blanke’s professional life, from early research to his current advocacy work.

Blanke’s interest in medicine was sparked by a personal diagnosis of Type 1 diabetes, which guided him toward internal medicine and eventually oncology. During his fellowship and early faculty years he became known for pursuing challenging research projects, even when initial attempts did not succeed.

At OHSU, Blanke led a pivotal effort to apply the targeted therapy imatinib, known commercially as Gleevec, to new cancer indications. This work marked a significant scientific milestone in his career and highlighted his commitment to advancing precision oncology.

Beyond the laboratory, Blanke has emerged as a prominent voice for medical aid in dying, arguing that dignified end‑of‑life options should be integrated into cancer care. He discusses how his clinical experiences shaped this advocacy and why he believes it is essential for patient autonomy.

The interview underscores the intersection of cutting‑edge cancer research with broader ethical considerations, offering listeners insight into how scientific leaders can influence policy and patient care beyond the bench.